In contrast to CH driven by mutations in epigenetic modifiers, CH driven by mutations in splicing factor genes SF3B1, SRSF2, and U2AF1 engenders a much higher risk of progression to MN, particularly MDS (144). Here, SRSF2 is linked to cyclic hematopoiesis.